HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
Andrea VecchiMarzia RossiCamilla TiezziPaola FisicaroSara DoselliElena Adelina GaborAmalia PennaIlaria MontaliCamilla Ceccatelli BertiValentina ReverberiAnna MontaliSimon P FletcherElisabetta DegasperiDana SambarinoDiletta LaccabueFloriana FacchettiSimona SchivazappaElisabetta LoggiBarbara CocoDaniela CavalloneElena Rosselli Del TurcoMarco MassariGiuseppe PedrazziGabriele MissaleGabriella VerucchiPietro AndreoneMaurizia Rossana BrunettoPietro LamperticoCarlo FerrariCarolina BoniPublished in: Gut (2024)
PegIFN-α treatment can induce greater functional T cell improvement and HBsAg decline in patients with lower baseline HBcrAg levels. Thus, HBcrAg may represent an easily and reliably applicable parameter to select patients who are more likely to achieve better response to pegIFN-α add-on to virally suppressed patients.